Calibrate - Comprehensive Analysis Report

Summary

Calibrate is a digital metabolic health company founded in 2019 with a mission to change how the world treats weight by improving metabolic health to drive long-term, sustainable weight loss. Calibrate combines FDA-approved prescription medication with behavioral therapy, offering lifestyle coaching and weight management services. Its one-year metabolic reset program is designed by experts in obesity and nutrition science, providing equitable access to treatment and sustained outcomes through its digital platform and holistic program.

1. Strategic Focus & Objectives

Core Objectives

• Provide a comprehensive and clinically-guided approach to obesity treatment

• Integrate medication with transformative behavior change to improve overall metabolic health

• Emphasize a value-based care model, aligning incentives for consumers, doctors, insurers, and pharmaceutical companies

• Target the underlying biology contributing to obesity, focusing on long-term, sustained weight loss results

• Shift focus toward enterprise sales, targeting employers and insurers

Specialization Areas

• Comprehensive approach to obesity treatment, combining medication with lifestyle intervention

• Integration of telemedicine and behavior change techniques

• Proprietary integrated vertical pharmacy engine to help members obtain medications

• Proprietary intensive lifestyle intervention to treat the underlying biology that contributes to obesity

Target Markets

• Individuals seeking weight loss and improved metabolic health

• Employers and insurers looking to provide weight management programs to their employees and members

• The $500 million weight loss prescriptions segment within the broader $270 billion weight loss market

2. Financial Overview

Funding History

Total funds raised: $156.6 million over 5 rounds.

• Seed Round: $5.1 million in June 2020, led by Forerunner Ventures.

• Series A: $22.5 million in January 2021, led by Threshold Ventures.

• Series B: $100 million in August 2021, co-led by Founders Fund and Tiger Global Management.

• Convertible Note: November 2022, amount not publicly disclosed.

• Private Equity Round: $29 million in November 2023, led by Madryn Asset Management and Samsung NEXT.

The funding is intended to scale operations, expand the team, enhance the virtual coaching platform, and grow the enterprise business.

3. Product Pipeline

Key Products/Services

• One-year Metabolic Reset program:

• Description: Includes FDA-approved medication, one-on-one video doctor visits, personal coaching on food, sleep, exercise, and emotional health, and app-based curriculum and progress tracking.

• Target: Individuals seeking a comprehensive weight loss and metabolic health program.

• Timeline: One year

• Key Features and Benefits: Aims for a 10% or more weight loss, with members reporting an average annual body weight loss of 14%.

• Calibrate Masters program:

• Description: Provides continued support after the initial year.

4. Technology & Innovation

Technology Stack

• Digital platform combining telemedicine and behavior change techniques

• Proprietary integrated vertical pharmacy engine

• Proprietary intensive lifestyle intervention

• Research-based model connecting patients with obesity specialists and coaches

5. Leadership & Management

Executive Team

• Rob MacNaughton: Chief Executive Officer

• Background: CEO of Curve Health and Nurse Grid, Chief Product Officer at Cambia Health Solutions.

• Kim Boyd: Chief Medical Officer.

• Charmaine Stafford: SVP, Head of Member Experience.

• Christine Celio: SVP, Head of Program Psychology.

• Donna Ryan: Clinical Advisor.

Recent Leadership Changes

• Isabelle Kenyon, the founder and former CEO, stepped down from her position in the fall.

• Rob MacNaughton assumed the role of CEO in January.

6. Competitive Analysis

Major Competitors

• Apree Health

• Noom

• Lose It!

• Trifecta Nutrition

• Second Nature

• Health2Sync

• Blue Mesa Health

• Liva Healthcare

7. Market Analysis

Market Overview

• 40% of US adults are obese, and 100 million Americans have diabetes or prediabetes.

• The total cost of chronic diseases due to obesity/overweight in the US is $1.72 trillion.

• Calibrate is targeting the $500 million weight loss prescriptions segment within the broader $270 billion weight loss market.

8. Strategic Partnerships

• OptumRx: A collaboration with OptumRx provides Calibrate's weight loss programs to employers.

• FedEx: Calibrate launched with FedEx as a strategic client through its OptumRx partnership.

• Collective Health: Integration with Collective Health allows members to access Calibrate's services through the My Collective™ portal.

9. Operational Insights

• Differentiation through a comprehensive approach combining medication with lifestyle intervention.

• Emphasis on a data-driven, outcomes-based model, focusing on long-term health improvements.

• Focus on the enterprise market and partnerships with pharmacy benefit managers provide a competitive advantage.

10. Future Outlook

Strategic Roadmap

• Focused on expanding its enterprise business and growing strategic partnerships with employers.

• Aims to serve hundreds of thousands, if not millions, of people through its programs.

• Leveraging data and technology to drive medical efficacy and efficiency.

• Focusing on curriculum, coaching, tracking, and community to drive engagement.